Several new agents have shown promise in studies
San Diego—Emerging data suggests that a range of new treatment options may be coming for patients with refractory multiple myeloma (MM) that has progressed after exposure to bortezomib, lenalidomide and other modern therapies for this disease.
Several new agents have shown promise in studies with clinically meaningful end points. Vorinostat, a histone deacetylase (HDAC) inhibitor, significantly improved progression-free survival (PFS) in a Phase III study, while pomalidomide, a derivative of thalidomide, demonstrated substantial activity in a Phase II study.
No comments:
Post a Comment